Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • pmiguel
    Senior Member
    • Aug 2008
    • 2328

    Using degraded RNA with TotalRNA Seq Kit

    The Total RNA Seq Kit (Ambion/LifeTech) is designed for constructing SOLiD RNA seq libraries. It produces strand-specific libraries by ligating the 5'-end of RNA fragments to 5'-end adapters[1]. This ligation requires the 5'-end of the RNA to be mono-phosphorylated. The ligation works because the RNAse chosen by Ambion to fragment the RNA prior to ligation is of a type that leaves a 5'-phosphate upon cleavage.

    This idea occurred to me recently--I am speculating, not reporting experimental results.

    One possible issue is that some RNA degradation may have occurred prior to the RNA fragmentation step. However, it is my understanding that most RNAses and chemical/heat modes of RNA degradation do not leave a 5'-monophosphate end. Rather they proceed via nucleophilic attack of the 2'-OH group on the phosphate backbone and result in 5'-hydroxyl, 3'-phosphate. Right?

    If so, these fragments will not be substrates for ligation to the adapters provided in the Total RNA Seq kit.

    This is not bad, per se, just something to keep in mind. If you did want to make an RNA Seq library from fairly heavily degraded RNA, you would want to treat it with an enzyme such as T4-polynucleotide kinase (PNK) prior to ligation. Subsequent removal of PNK might also be critical because it could otherwise allow increased amounts of adapter-dimers to form. (Or not. I do not know the details of the structure of these adapters.)

    --
    Phillip

    [1]Note that this implies that to ligate to the 5' ends of capped RNA molecules, those RNAs would need to be de-capped (with, eg, Tabacco Acid Pyrophosphatase) first.

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-09-2026, 10:04 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-08-2026, 10:08 AM
0 responses
29 views
0 reactions
Last Post SEQadmin2  
Working...